FiercePharma

The biopharmaceutical industry is rapidly evolving, bringing fresh concepts to light every day. Subscribers turn to FiercePharma as their essential resource for the most current news, insights, and data regarding medications and the companies behind them. Each business day, FiercePharma and its associated publications provide comprehensive coverage of the pharmaceutical sector, spanning from late-stage drug development to all stages of the product lifecycle. Stay informed about topics such as regulatory approvals, negotiations with payers, manufacturing processes, marketing strategies, patent disputes, government inquiries and regulations, mergers and acquisitions, and much more.

International, Trade/B2B

English

Newsletter (Digital)

Outlet metrics

Domain Authority

Ranking

Global

#97238

United States

#28888

Health/Health

#680

Traffic sources

Monthly visitors

Articles

Argenx joins NBC health marketing platform to produce CIDP reality show

1 day ago | fiercepharma.com | Andrea Park

Argenx has signed on as an early partner to a newly launched initiative from media companies NBCUniversal Local and Digital Health Networks (DHN) that plans to offer healthcare marketing in the form of video and digital storytelling content.
Inside ASCO 2025: Big data drops and a towering campaign

1 day ago | fiercepharma.com | Ayla Ellison |Angus Liu |Gabrielle Masson |Zoey Becker

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in cancer research, and this year was no exception. In this episode of "The Top Line," Fierce reporters take you inside the action at ASCO 2025. Zoey Becker shares the story behind Johnson & Johnson’s dramatic “Breathtaking” campaign, staged on the 99th floor of Chicago’s Willis Tower.
Fierce Pharma Asia—Bispecific field's roller coaster week; Enhertu's first-line win; Regeneron-Hansoh obesity deal

1 day ago | fiercepharma.com | Angus Liu

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. AstraZeneca and Daiichi Sankyo trotted out Enhertu's detailed data in first-line breast cancer. Regeneron signed on a GLP-1/GIP candidate from China's Hansoh Pharma. And more. 1.
Fujifilm, Coherus, ViGeneron unveil rebrands to better reflect ongoing work

2 days ago | fiercepharma.com | Andrea Park

After a long winter, the start of summer is ushering in some much-needed sunshine, warmer weather and, for a handful of biopharma companies, refreshed branding. In the last week, a trio of companies across the industry have unveiled either slightly tweaked or completely new names, including the drugmakers formerly known as Coherus BioSciences and ViGeneron, and certain businesses within Fujifilm’s life sci group.
With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field

2 days ago | fiercepharma.com | Angus Liu

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes how far the fanfare will spread. It’s more than just existing PD-1/L1 players potentially looking for bispecifics to bolster their positions; whether checkpoint inhibitor wannabes will use these next-generation antibodies to make up for lost PD-1 opportunities—and potentially leapfrog makers of anti-PD-1 drugs—remains an open topic for discussion.
Novo Nordisk signs on to support ADA’s obesity advocacy division

3 days ago | fiercepharma.com | Andrea Park

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo Nordisk for support. The ADA’s obesity division went live last June, with a mission of advocating for more equitable access to obesity treatments and greater awareness and education around the condition, all of which the association is hoping will help break down stigmas linked to obesity and enable people to get the care and support they need.
Want to attract Gen Z talent to life sci? Try short-form social media videos, ABPI report suggests

4 days ago | fiercepharma.com | Andrea Park

Pharmas looking to recruit younger workers should meet members of Generation Z where they’re at: namely, TikTok and Instagram, according to a new report from the Association of the British Pharmaceutical Industry (ABPI). The report was based on recent surveys of teenagers and young adults aged 16 to 25 and STEM teachers and academic career counselors in the U.K., plus a STEM-centric focus group of 14- to 25-year-olds.
ASCO: J&J's Akeega gives PARP a novel prostate cancer win, but FDA path in patient subset unclear

4 days ago | fiercepharma.com | Angus Liu

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson & Johnson’s Akeega is giving the class a win in castration-sensitive disease, although the drug’s benefit in a patient subgroup remains unclear.
ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop

4 days ago | fiercepharma.com | Angus Liu

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the needle in resected skin cancer. After revealing in February that Opdualag failed as a postsurgery adjuvant treatment for patients with completely resected stage 3 and 4 melanoma, BMS has peeled back full results from the negative Relativity-098 trial at the 2025 American Society of Clinical Oncology annual meeting.
Endo maps out Men’s Health Month awareness drive

4 days ago | fiercepharma.com

Endo is taking advantage of June’s status as Men’s Health Month to encourage men to prioritize their physical, mental and sexual health.